Who are the top investors in synthetic biology?
Whether you're building or investing in the synthetic biology market, our report covers everything you need to know: the players, the money, and what's coming next.
Summary
SOSV is the top synthetic biology investor today, followed by Flagship Pioneering, with DCVC, Khosla Ventures, Main Sequence and KdT Ventures forming the strongest group behind them.
The ranking changes depending on what kind of synthetic biology company we mean. SOSV dominates early company formation, Flagship is strongest in programmable biology, Main Sequence is unusually well positioned in industrial biomanufacturing, and RA Capital rises sharply when therapeutics enter the definition.
Recent activity is much more concentrated than the long list of famous synthetic biology backers suggests. Across the latest rolling 12-month pure-play dataset, SOSV was the only publicly identifiable investor that appeared in three qualifying rounds.
The funding market itself is similarly concentrated. Nineteen disclosed equity rounds raised about $1.01 billion, but NewLimit alone accounted for 42.9% of the capital and the three largest deals captured 68.4%.
That concentration makes repeat investing more informative than one giant check. Founders Fund can lead a $435 million round and still tell us less about category-wide investing behavior than a specialist repeatedly backing companies at seed or pre-seed.
Early-stage synthetic biology is still alive. Seed and Series A represented 13 of the 19 recent financings, even though later-stage Series B and C rounds captured most of the dollars.
The best investors increasingly separate by bottleneck. Industrial companies need help with fermentation economics, infrastructure and scale-up; therapeutic platforms need clinical development and pharma relationships; very early science companies need investors comfortable funding technical risk before commercial metrics exist.
Flagship may be the most powerful organization in the sector even though we rank it second overall. Its company-creation model, $3.6 billion capital expansion and ability to build programmable-biology companies internally put it in a category of its own, but that model is less accessible to an independent founder.
Specialist funds still matter more than fund size would suggest. KdT, Breakout, Fifty Years and Genoa have portfolios that show unusually concentrated technical conviction, which can be more useful at formation stage than a much larger generalist fund with only occasional exposure.
The practical lesson for founders is that the global ranking should not become the pitch list. The best first call depends on whether the next hard problem is company formation, biological manufacturing, clinical development, computation, or financing a breakout platform at scale.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
Want to know which startups could overtake the giants next? It's all in our synthetic biology market report.
What does “top synthetic biology investor” actually mean today?
Today, a top synthetic biology investor has to show repeated activity in the sector, enough technical depth to invest before the science is obvious, and enough capital or operating support to remain useful as the company grows.
The word “top” becomes slippery very quickly here. SOSV can make a strong claim based on the number of companies it has helped start. Flagship Pioneering operates at a completely different scale and often creates the company itself. KdT Ventures has a smaller fund but one of the most concentrated portfolios in engineered biology. Main Sequence stands out in industrial biomanufacturing. RA Capital becomes far more relevant once programmable medicines enter the definition.
We therefore looked at several kinds of evidence together: recent investments, repeat appearances across deals, portfolio depth, how early each investor gets involved, whether it leads rounds, its ability to follow companies into larger financings, and how much of its portfolio genuinely depends on engineering biology.
Recent activity deserves extra weight. A fund that backed three famous synthetic biology companies during the previous boom should rank below a fund that has kept finding new companies through the much tougher market of the past few years.
| What we are measuring | Why it helps | Investors that stand out |
|---|---|---|
| Recent repeat activity | Shows who is still actively buying the category | SOSV |
| Early company creation | Shows who finds companies before the market does | SOSV, Flagship, Fifty Years |
| Specialist synbio depth | Shows repeated technical conviction | KdT, Breakout, Genoa |
| Ability to fund large companies | Becomes important after technical validation | Flagship, Khosla, RA Capital, DCVC |
| Industrial scale-up experience | Critical for fermentation, materials and agriculture | Main Sequence, DCVC, Breakout, KdT |
Is synthetic biology funding actually healthy right now?
Synthetic biology funding is alive today, but money is flowing to a surprisingly small number of companies and the headline totals make the market look broader than it really is.
Our latest pure-play review found 19 publicly disclosed equity rounds worth about $1.01 billion over the latest 12-month period. That sounds substantial until we look at the distribution. NewLimit's $435 million Series C alone represented 42.9% of all the capital. The three largest rounds accounted for 68.4%, while the top ten absorbed 92.5%.
The typical deal was far smaller. The median round was $19 million, compared with an average of $53.4 million. Removing every round above $50 million cuts the total from roughly $1.01 billion to $210.6 million.
Deal count tells a similar story. Seed and Series A accounted for 13 of the 19 financings, so new companies are still getting institutional backing. Yet Series B and Series C captured 70.7% of the dollars. Investors are willing to place very large bets once they see something exceptional, while ordinary synthetic biology companies still face a selective fundraising market.
That environment changes our investor ranking. Recent repeat investing is valuable precisely because there are so few deals to repeat into.
Not every big name makes it. Our synthetic biology market report looks at who stumbled, why, and what the survivors did differently.
Are the same synthetic biology VCs actually showing up again and again?
Very few synthetic biology investors are repeatedly appearing in current pure-play deals, and SOSV is the clearest exception.
Our review of the latest 12 months found SOSV in three qualifying rounds: Scindo, Cauldron Ferm and Fermeate. No other publicly identifiable investor appeared in more than one qualifying deal during that specific window.
A longer comparison shows a little more continuity. In 2024, KdT Ventures and Digitalis Ventures were the only repeat names in our qualifying dataset. In 2025, repeat activity widened, with SOSV appearing three times and RA Capital, Khosla Ventures, ReGen Ventures, Main Sequence, the European Innovation Council Fund, Azolla Ventures and Zero Carbon Capital appearing twice. Current year-to-date data has again become sparse, with SOSV and Good Startup the only repeat names so far.
Public disclosures are incomplete, so this is not a complete cap-table census. Some announcements name only the lead investor, while others leave smaller participants undisclosed. Still, the pattern is clear enough to use: synthetic biology has many occasional investors and a much smaller group that keeps coming back.
| Period reviewed | Repeat investors we could identify | What we learn |
|---|---|---|
| 2024 | KdT Ventures, Digitalis Ventures | Repeat activity was very thin |
| 2025 | SOSV plus several two-deal investors | More funds started making multiple bets |
| Current year so far | SOSV, Good Startup | Repeat activity remains concentrated |
| Latest rolling 12 months | SOSV alone appeared 3 times | SOSV has the strongest visible recent frequency |
Is SOSV still the most active early-stage synthetic biology investor?
SOSV is currently the strongest overall answer if we care most about early-stage synthetic biology activity and the repeated creation of new companies.
The history is unusually deep. SOSV says that 310 companies graduated from IndieBio between 2015 and 2025 and collectively raised $3.6 billion after going through the program. IndieBio combined pre-seed investment with wet-lab space, which allowed scientists to start companies before they could afford their own laboratory infrastructure.
The name changed recently as IndieBio's San Francisco and New York programs were folded into the broader SOSV SF and SOSV NY brands. Biology remains a major part of what those teams do. The latest cohorts still include companies working in engineered biology, proteins, healthcare, food and agriculture, alongside a wider set of deep-tech startups.
More importantly, the investing behavior still matches the reputation. SOSV backed Scindo, Cauldron Ferm and Fermeate across our latest pure-play funding window. That recent activity gives its historical company count much more weight.
SOSV also has more financial room than its old accelerator image suggests. The firm says it currently manages about $1.5 billion, with its latest core fund at $306 million. Its Genesis Consortium also links early life-science companies with investors including Mayfield, DCVC and corporate venture groups.
For a scientist forming a synthetic biology startup today, SOSV remains one of the first investors we would look at. Its edge comes from seeing companies extremely early and doing it repeatedly.
If you want more recent data on this point, please see our latest synthetic biology market report.
Some of the most hyped startups in this space lost most of their value. Find out what went wrong in our synthetic biology market report.
Is Flagship Pioneering the most powerful investor in programmable biology?
Flagship Pioneering is probably the most powerful company-building platform in programmable biology today, especially when synthetic biology includes engineered medicines and new biological modalities.
Flagship operates differently from almost every other investor in this article. Its teams develop scientific ideas internally, form companies around them and often remain the principal owner and resource provider. Founders approaching Flagship from outside are therefore dealing with a different model from pitching a conventional VC fund.
The capital behind that model is enormous. Flagship expanded its capital base by $3.6 billion in 2024, including a $2.6 billion eighth fund and another $1 billion tied to side funds and strategic partnerships. The firm said that capital could support the creation and development of roughly 25 companies.
Its current activity shows where that money is going. Flagship launched Serif Biomedicines this year after five years of internal work and committed an initial $50 million. Serif is developing modified DNA medicines designed to combine programmability, durability and redosing. Flagship's portfolio already includes Moderna, Tessera Therapeutics, Generate:Biomedicines, Inari Agriculture and Quotient Therapeutics.
A particularly fresh example is Sail Biomedicines. Johnson & Johnson recently agreed to a collaboration around Sail's RNA technology that includes a $465 million equity investment, other upfront and milestone-related payments, and an exclusive option to acquire Sail for an additional $2.58 billion. Whatever happens clinically, that transaction shows how much strategic value large pharmaceutical companies are now assigning to programmable biological platforms.
Flagship ranks just behind SOSV in our overall list because the question asks about investors founders can realistically encounter across the market. On sheer company-building power, Flagship could easily be number one.
Is Khosla Ventures still one of the best big funds for synthetic biology?
Khosla Ventures remains one of the best large generalist investors for ambitious synthetic biology companies, although its current pure-play deal frequency is less dominant than SOSV's.
Khosla has spent years backing companies where biology behaves more like an engineering platform than a traditional drug-development program. Its portfolio stretches across food technology, genetic medicine, biological manufacturing, computational biology and new experimental systems.
Vivodyne is a good example of how Khosla invests. The firm led Vivodyne's $38 million seed round and then led another $40 million Series A as the company expanded its automated platform for testing drugs on bioengineered human tissues. Khosla moved in before conventional commercial validation and kept supporting the company as it built more expensive infrastructure.
Our 2025 dataset also found Khosla appearing in multiple qualifying synthetic biology deals. Recent rolling data is thinner, so we would not give Khosla the same current-activity score as SOSV.
Khosla's appeal becomes strongest when a synthetic biology company could grow beyond a narrow biotech niche. A founder building a new biological manufacturing system, automated biological platform or radical therapeutic technology can plausibly fit the firm's broader view of frontier technology.
That combination of risk tolerance and follow-on capacity keeps Khosla near the top of our ranking even in periods when it is not the most frequent investor.
If you want more recent data on this point, please see our latest synthetic biology market report.
Is investor excitement matched by real public interest? Find out in our synthetic biology market report.
Does DCVC still deserve a top spot in synthetic biology?
DCVC still deserves a top synthetic biology ranking because its biology portfolio has survived several market cycles and the firm is making fresh investments today.
Its history goes back well before the 2021 synthetic biology boom. DCVC first invested in Pivot Bio in 2014, backing the idea that engineered soil microbes could reduce the amount of synthetic nitrogen fertilizer farmers need. It also backed Zymergen early, one of the defining industrial synthetic biology companies of the previous cycle.
Zymergen ultimately became a warning about how difficult synthetic biology economics can be. That history actually makes DCVC more interesting now. The firm has seen the ugly side of scaling engineered biology and kept investing in the field.
Current activity is easy to find. DCVC led an $80 million seed financing for Proxima, a company trying to systematically reprogram protein-protein interactions. DCVC also co-led $48 million of new funding for Kanvas Biosciences, which combines microbiome mapping with manufacturing of live biotherapeutic communities. Syntax Bio, a synthetic biology company programming cell therapies, also expanded its Series A this year with continued support from DCVC Bio and other investors.
DCVC Bio explicitly lists synthetic biology alongside human health and agriculture as one of its areas of investment. The team includes experience in genetics, molecular biology, agriculture and industrial fermentation, which is particularly useful for companies that eventually have to manufacture biology rather than simply demonstrate it in a lab.
We rank DCVC above most generalist deep-tech funds because both its old portfolio and its recent investments show that the category is still part of the firm's actual behavior.
Is KdT Ventures still a top synthetic biology specialist?
KdT Ventures is still one of the best specialist investors for early synthetic biology, although we would rank it lower on current deal velocity than we would have a few years ago.
The portfolio explains why KdT remains important. It has backed Solugen, Checkerspot, Debut Biotechnology, Dyno Therapeutics, Elegen, Tierra Biosciences, ZymoChem, Andes and several other companies that depend heavily on molecular engineering, biological production or next-generation life-science tools.
KdT also tends to enter very early. The firm says it is often the first institutional investor and commonly leads or co-leads pre-seed and seed rounds. That is a valuable position in synthetic biology, where a new company's first major question is often whether a technically unusual scientific platform deserves to become a venture-backed business at all.
The fund added more than $100 million for new early-stage investments at the end of 2024. Its current portfolio still has plenty of active synthetic biology exposure, but its latest public deal record is broader across frontier science and therapeutics.
So we would describe KdT today as a top specialist based on portfolio quality and early-stage judgment. Investors looking strictly for the highest number of fresh pure-play synbio deals will find stronger recent evidence elsewhere.
Where the money goes says a lot about who will win. Our synthetic biology market report breaks it down by region.
Is Main Sequence becoming the key investor in industrial synthetic biology?
Main Sequence is currently one of the most convincing investors in industrial synthetic biology, especially for fermentation, food, agriculture and biological manufacturing.
The portfolio already gives it unusually broad exposure to that part of the market. Main Sequence backs Cauldron, Number 8 Bio, Loam Bio, Levur, ULUU, Nourish Ingredients and The EVERY Company, among others. These companies use biology in very different products, but all eventually run into manufacturing costs, physical infrastructure or supply-chain constraints.
Cauldron is the freshest example. Main Sequence recently led a $13.25 million Series A2 for the Australian company, which is developing continuous “hyper-fermentation” designed to keep engineered microbes productive for much longer than conventional batch systems. Horizons Ventures, SOSV and NGS Super also participated.
The investment is revealing because Cauldron sells infrastructure for other biological producers. Main Sequence is effectively betting on the bottleneck many precision-fermentation companies hit when they leave the lab: keeping output high enough and costs low enough to compete in real manufacturing.
Main Sequence also has enough capital to follow these companies. The firm says its $450 million third fund took assets under management above $1 billion, and it invests from seed through Series B.
For a founder trying to manufacture proteins, ingredients, materials or agricultural products with biology, Main Sequence belongs near the top of the outreach list today.
If you want more recent data on this point, please see our latest synthetic biology market report.
Who is leading therapeutic synthetic biology investing right now?
Flagship Pioneering currently has the strongest position in therapeutic synthetic biology, with RA Capital, DCVC, Khosla Ventures and Lux Capital forming a powerful second group around programmable medicines and techbio.
Therapeutics now absorb an outsized share of synthetic biology capital. In our latest pure-play dataset, only four therapeutic deals represented 21.1% of deal count but captured $664.1 million, or 65.5% of all disclosed funding. NewLimit, Strand Therapeutics, Think Bioscience and Telum Therapeutics drove that total.
Flagship has the deepest company-creation model here. Serif, Tessera, Generate and Sail all involve different ways of designing or programming biological systems for medicine. The recent Sail transaction with Johnson & Johnson also gives Flagship unusually strong evidence that pharmaceutical buyers are willing to place very large strategic bets on these platforms.
RA Capital becomes highly relevant once synthetic biology moves into drug development. RA says it deployed more than $650 million into private financings in 2025 and manages more than $14 billion. Its company-building arm is also supporting Synolo Therapeutics, a young company using computational protein design and high-throughput biological datasets to build multispecific cancer drugs. Synolo's founding team includes researchers with backgrounds in protein engineering, DNA sequencing and synthetic biology.
DCVC's current activity around Proxima, Kanvas and Syntax Bio gives it another strong claim. Khosla and Lux remain attractive where biology overlaps with computation, automation or entirely new therapeutic platforms.
Founders should be careful with the old mental model of synthetic biology as microbes making chemicals. A huge share of the venture money now sits much closer to programmable medicine.
Price is often what holds a market back. See how fast that's changing in our synthetic biology market report.
Which smaller synthetic biology funds are easy to overlook?
Breakout Ventures, Fifty Years and Genoa Ventures are three smaller funds we would take very seriously for synthetic biology because their portfolios show far more category depth than their fund sizes suggest.
Breakout Ventures has one of the cleanest specialist portfolios. It has backed ZymoChem, Checkerspot, A-Alpha Bio, Modern Meadow, STRM.BIO, EnPlusOne Bio and Immusoft. Some make materials, some make therapeutics and some build biological discovery tools, but the common thread is clear: difficult science has to become a commercially useful product.
ZymoChem captures that approach particularly well. Breakout led its $21 million Series A, joined by investors including Toyota Ventures, lululemon and existing investor KdT Ventures. ZymoChem is trying to improve the economics of biological production for performance chemicals, so the company has to solve both metabolic engineering and manufacturing economics.
Fifty Years has been unusually early around biological infrastructure. It led Ansa Biotechnologies' pre-seed round years before Ansa's enzymatic DNA synthesis platform reached its current scale. Fifty Years' portfolio today still includes companies working on alternative genetic codes, engineered enzymes, synthetic immunology, DNA synthesis and synthetic-biology-powered mRNA therapeutics. Its 5050 program has also helped create dozens of science companies from researchers who had not necessarily planned to become founders.
Genoa Ventures is even more explicit about its thesis. The fund describes synthetic biology, genetic engineering, biomanufacturing and industrial biology among its areas of investment. Genoa's founder, Jenny Rooke, has recently described biology as a general-purpose technology that increasingly combines with software, automation, chemistry and engineering.
None of these firms can deploy capital on Flagship's scale. For a scientist raising a first institutional round, that comparison is often irrelevant. Technical understanding and willingness to invest early can matter much more.
If you want more recent data on this point, please see our latest synthetic biology market report.
Do the biggest synthetic biology rounds tell us who the best investors are?
The biggest synthetic biology rounds tell us where investors are willing to concentrate capital today, but they are a poor standalone ranking of who really understands the sector.
Consider NewLimit. Its $435 million Series C was the largest deal in our latest pure-play dataset and accounted for more than two-fifths of all capital raised in the period. Founders Fund led the round, with Thrive Capital, Greenoaks and other major investors participating.
Strand Therapeutics raised another $153 million for programmable mRNA therapeutics, with Kinnevik leading and strategic investors including Regeneron, Amgen Ventures and Eli Lilly joining the syndicate. Profluent raised $106 million around AI models for programmable biology.
Those are major votes of confidence. They mainly tell us that a small group of companies can now attract enormous checks when investors see enough technical progress and commercial upside.
The broader market behaves very differently. As seen above, only 19 qualifying rounds appeared across the latest 12-month review, and the median financing was $19 million. A large late-stage investor can therefore put hundreds of millions into one exceptional company without becoming a frequent synthetic biology investor.
For our ranking, repeated category behavior carries more weight than participation in one blockbuster financing. That is why SOSV, Flagship, DCVC, KdT and Main Sequence rank highly even when another fund may have written a much larger individual check.
Want to avoid the mistakes that sank others? Our synthetic biology market report breaks down what went wrong.
Which synthetic biology investors are best at getting companies through scale-up?
Main Sequence and DCVC stand out for industrial synthetic biology scale-up, while Flagship has the strongest model for taking programmable biology through expensive therapeutic development.
Industrial synthetic biology becomes much harder once a company moves beyond proving that an organism can make something. Yield, feedstocks, contamination, downstream purification, equipment, energy use and customer pricing start deciding whether the business works.
Main Sequence's Cauldron investment directly targets that problem. Cauldron is trying to make continuous fermentation work inside infrastructure that can eventually handle commercial production. The company has also been working with partners on retrofitting existing facilities instead of assuming every customer will build an entirely new plant.
DCVC has accumulated similar experience through companies such as Pivot Bio, MycoWorks and BioPhero. Pivot Bio has been in the portfolio since 2014, giving DCVC more than a decade of exposure to the difficulty of moving engineered microorganisms from science into mainstream agriculture.
Breakout and KdT also score well here. Their shared ZymoChem investment is a good example: the goal is commercially viable biomanufacturing with higher yields, which forces the investors to think about economics as early as they think about biology.
Therapeutics have another scale-up path. Flagship's companies can draw on a much larger internal ecosystem for clinical development, manufacturing, partnerships and follow-on financing. The recent Sail deal shows what that can look like when a platform becomes strategically interesting to a pharmaceutical company.
A synthetic biology investor becomes far more valuable when the investor has already watched another portfolio company hit the same manufacturing or development wall.
Which synthetic biology investor should a founder pitch first?
The best synthetic biology investor to approach first depends heavily on what the company is building, and choosing purely from a global ranking would waste a lot of fundraising time.
A scientist with an early engineered-biology idea should probably start with funds such as SOSV, KdT, Fifty Years, Breakout or Genoa. These investors are comfortable looking at companies before commercial metrics exist, and several have infrastructure or technical teams designed for that stage.
Industrial fermentation, ingredients, materials and agricultural biology push Main Sequence and DCVC much higher. KdT and Breakout also fit well because they already own stakes in companies dealing with biological production economics.
Programmable therapeutics call for a different list. RA Capital becomes much more useful once a company needs serious drug-development expertise. DCVC has fresh activity in this area. Khosla works well for platforms that combine biology with engineering or computation. Flagship is extraordinarily powerful when the company fits its internal creation model.
SOSV has another practical advantage for companies that are still being formed. As pointed out above, it was the only investor we could clearly identify in three qualifying deals across our latest rolling pure-play dataset. That tells founders something concrete about current willingness to keep writing early checks.
There is no reason to chase the highest-ranked logo if that fund has never dealt with the next problem your company will face.
Big promises are easy to make. Our synthetic biology market report checks which ones were actually kept.
So who are the top investors in synthetic biology right now?
SOSV is our number-one synthetic biology investor today, followed by Flagship Pioneering, with DCVC, Khosla Ventures, Main Sequence and KdT Ventures making up the strongest group immediately behind them.
SOSV earns the top position because current behavior and long-term history point in the same direction. It has built hundreds of science companies through IndieBio and its successor programs, and it remains the clearest repeat investor in recent pure-play synthetic biology rounds.
Flagship is arguably the more powerful organization. Its billions of dollars in capital, internal company-creation process and current programmable-biology portfolio give it an unmatched ability to turn a scientific idea into a heavily financed company. We place it second mainly because Flagship's model is less accessible to the ordinary independent founder.
DCVC moves into our top three because we can see both long-term synthetic biology conviction and fresh activity. The portfolio spans industrial biology, agriculture and programmable medicine, while recent financings show the firm is still making new biological bets.
Khosla remains the strongest large generalist for us. Main Sequence moves very high for anyone focused on industrial biology because its current portfolio and Cauldron investment show real commitment to biological manufacturing. KdT stays in the first group based on specialist depth and exceptional early-stage exposure, although its recent pure-play deal frequency is lower.
After those six, the ranking becomes much more dependent on what we decide synthetic biology includes. RA Capital rises sharply in programmable medicine. Breakout becomes more attractive in industrial biology and science-heavy seed deals. Fifty Years is especially interesting around company formation and new biological tools. Lux remains important where AI and biology meet. Genoa deserves attention from founders building companies that sit awkwardly between conventional biotech and deep tech.
That fragmentation is probably the most useful conclusion in the entire exercise. There are plenty of famous investors around synthetic biology, yet only a small group repeatedly behaves as if engineering biology itself is a market worth hunting for.
| Rank | Investor | Why we rank it here | Best fit today |
|---|---|---|---|
| 1 | SOSV / former IndieBio | Strongest mix of recent repeat activity and long-term company formation | Pre-seed and seed synthetic biology |
| 2 | Flagship Pioneering | Most powerful programmable-biology company builder | New biological platforms and therapeutics |
| 3 | DCVC / DCVC Bio | Long history plus fresh activity across engineered biology | Industrial biology, agriculture, techbio |
| 4 | Khosla Ventures | Best large generalist for radical biology companies | Cross-disciplinary platform companies |
| 5 | Main Sequence | Especially strong current exposure to biological manufacturing | Fermentation, food, agriculture, materials |
| 6 | KdT Ventures | One of the deepest specialist early-stage portfolios | Seed-stage engineered biology |
| 7 | RA Capital | Huge healthcare investing capacity and growing programmable-biology relevance | Therapeutic synthetic biology |
| 8 | Breakout Ventures | Highly concentrated science-driven biology portfolio | Industrial synbio, tools, therapeutics |
| 9 | Fifty Years | Strong company-formation record around biological tools and deep tech | Pre-seed scientific spinouts |
| 10 | Lux Capital | Strong where biology converges with AI and frontier technology | Techbio and computational biology |
| 11 | Genoa Ventures | Explicit early-stage thesis around biology as technology | Synbio tools, industrial bio, bioconvergence |
| 12 | Founders Fund | Can write very large checks into exceptional biology companies | Later-stage breakout platforms |
If you want more recent data on this point, please see our latest synthetic biology market report.
Our methodology
This ranking looks at who the top investors in synthetic biology are today by combining recent investment activity, repeat participation, specialist portfolio depth, early-stage willingness, company-creation capability, follow-on capacity and experience supporting companies through technical or manufacturing scale-up.
We gave extra weight to recent and directly observable activity. Newly announced financings, repeat appearances across qualifying deals, current portfolio exposure, fresh fund capacity, company launches and follow-on investments mattered more than reputation built during the previous synthetic biology boom.
We treated frequency and check size as separate pieces of evidence. One very large financing can show conviction in a specific company, but repeated appearances across the category tell us more about whether a fund is still actively hunting for synthetic biology companies.
For the funding analysis, we focused on companies where engineering biology is fundamental to the underlying technology or product. Programmable therapeutics were included when engineering biological systems was central to the platform, which is why firms such as Flagship Pioneering and RA Capital become more relevant in the therapeutic part of the ranking.
The latest pure-play review covered 19 publicly disclosed equity rounds worth about $1.01 billion over the rolling 12-month period discussed above. Public financing announcements do not always disclose every participant, so repeat-investor counts are based on investors we could identify from public deal information rather than a complete census of every cap table.
We did not use a rigid points system. The final ordering comes from where several kinds of evidence reinforce one another: recent activity, repeated category exposure, early-stage judgment, portfolio quality, capital capacity and evidence that the investor has stayed involved as companies move into harder technical, manufacturing or clinical stages.
Key sources include SOSV on IndieBio becoming SOSV SF and SOSV NY, including 310 graduates and $3.6 billion raised, Flagship Pioneering on its $3.6 billion capital expansion, Flagship on the launch of Serif Biomedicines, Johnson & Johnson on the Sail Biomedicines collaboration, DCVC on Proxima's $80 million seed financing, DCVC on Kanvas Biosciences, KdT Ventures on more than $100 million added for early-stage investing, Main Sequence on its $450 million third fund and more than $1 billion under management, RA Capital on its private-financing activity and assets under management, Fifty Years on its early-stage science investment model, Fifty Years on the 5050 company-creation program, Strand Therapeutics on its $153 million Series B, and NewLimit on its $435 million Series C led by Founders Fund.
Some segments are hot, others are drying up. We track them all in our synthetic biology market report.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us